微粒化非诺贝特与标准化非诺贝特对原发性高脂血症疗效及安全性比较

为了比较微粒化非诺贝特与标准化非诺贝特对原发性高脂血症的疗效和安全性，将68例原发性高脂血症患者分别进行治疗，微粒化非诺贝特级38例，200mg，每晚服一粒；标准化非诺贝特组30例，每日300mg，分3次服，疗程均为8周。疗程结束时两组服药前后自身比较，血清总胆固醇平均降低分别为22．5％与17．7％；甘油三酯平均降低分别为53．5％与42．2％；高密度脂蛋白-胆固醇平均升高分别为21．2％与17．9％；谷丙转氨酶前组平均降低6．8％，后组平均升高19．4％，表明：微粒化非诺贝特较标准化非诺贝特具有更好的调脂作用，且安全方便。

Efficacy and tolerance of micronised fenofibrate compared with standard fenofibrate administered in hyperlipidemic patients

The aims of the study were to observe tbe clinical efficacy and safety of micronised fenofibrate and standard fenofibrate administered in hyperlipideforc patients. 38 patients with micronised fenofibrate(200 mg every night)and 30 patients with standard fenofibrate (100 mg tid). After 8-week treatment,the efficacies of self-controlled in two group were:the average decrease of serum total cholerterol of the patients was 22. 5%and 17.7% respectively; the average decrease of serum total triglyceride of the patients was 53.5% and 42.2% respctively;the average increase of serum high-density lipoprotein was 21. 2% and 17. 9% respectively; the average increase of serum SGPT was - 6. 8% and 19. 4% respectively. In conclusion,micronised fenofibrate is one of better lipids adjusting drug compared with standard fenofibrate. It is one of efficient,safe and convenint-administration lipids adjusting drug.